Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The closest pipeline candidates are orforglipron, the first non-peptide oral GLP-1 from Eli Lilly, with an FDA decision anticipated in 2026, and retatrutide, a triple GLP-1/GIP/glucagon agonist in phase 3
:max_bytes(150000):strip_icc():focal(748x241:750x243)/Serena-Williams-1-012726-2698f17c5ab647929a79194c436d85ea.jpg)
No diets, no agendas, just science that makes you feel better
This was in part spurred on by the fact that while exenatide was highly successful it had a significant downside
It also aids in weight loss by slowing gastric emptying and increasing feelings of fullness, making it a valuable therapeutic option for managing diabetes and obesity
Both medications are injected weekly, but semaglutide has demonstrated superior outcomes in clinical trials, with patients losing an average of 1522% of body weight compared to Saxenda's 510% reduction in dedicated weight loss studies
Your GLP-1 dosing and truSculpt treatment plan are all fully tailored to your needs
US$ 23.20
US$ 25.41
US$ 28.85
US$ 20.74
